Financial Results, Management Transitions, and Conference Call Schedules - Research Reports on Omnicare, MEDNAX, DaVita, IPC The Hospitalist Company and Healthways

NEW YORK, July 29, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Omnicare Inc. (NYSE: OCR), MEDNAX, Inc. (NYSE: MD), DaVita HealthCare Partners Inc. (NYSE: DVA), IPC The Hospitalist Company, Inc. (NASDAQ: IPCM) and Healthways Inc. (NASDAQ: HWAY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5204-100free.

--
Omnicare Inc. Research Reports
On July 23, 2014, Omnicare, Inc. (Omnicare) reported its Q2 2014 financial results with net sales growth of 7.1% YoY to $1.6 billion. Adjusted EBITDA from continuing operations totaled $176.2 million compared to $168.8 million in Q2 2013. Adjusted cash earnings per diluted share from continuing operation were $0.91, up 7.1% YoY. GAAP earnings per share from continuing operations were $0.58 compared to $0.43 in Q2 2013. Rocky Kraft, Omnicare's CFO, stated, "We intend to remain focused on cash flow efficiency while ensuring we are opportunistic with respect to increasing returns through working capital strategies. We believe this balance will enable us to continue improving returns through a systematic approach to capital deployment." The Company anticipates its full year 2014 revenues to be in the range of $6.3 billion to $6.4 billion and adjusted cash earnings per diluted share in the range of $3.64 to $3.72. The full research reports on Omnicare are available to download free of charge at:

http://www.analystsreview.com/Jul-29-2014/OCR/report.pdf

--
MEDNAX, Inc. Research Reports
On July 7, 2014, Mednax, Inc. (MEDNAX) announced its plan to release its Q2 2014 financial results on July 31, 2014, Thursday, before the markets open. Following the earnings release, the Company will hold an investor conference call and webcast on the same day at 10:00 a.m. EDT to discuss the results. The webcast of investor conference call can be accessed at the Company's website. The full research reports on MEDNAX are available to download free of charge at:

http://www.analystsreview.com/Jul-29-2014/MD/report.pdf

--
DaVita HealthCare Partners Inc. Research Reports
On July 18, 2014, DaVita HealthCare Partners (DaVita) announced that the President and CEO of its subsidiary HealthCare Partners (HCP), Dr. Craig Samitt, will be stepping down from HCP, effective August 1, 2014. The Company informed that Kent Thiry, Co-Chairman and CEO of DaVita, will take over the role of CEO of HCP and will work along with the Office of Chief Medical Officer. "I want to thank Craig for his contributions during his time here. He is a strong CEO and we wish him the best in his future endeavors," commented Thiry. The full research reports on DaVita are available to download free of charge at:

http://www.analystsreview.com/Jul-29-2014/DVA/report.pdf

--
IPC The Hospitalist Company, Inc. Research Reports
On July 23, 2014, IPC The Hospitalist Company, Inc. (IPC The Hospitalist Company) reported its Q2 2014 financial results with net revenue growth of 18.2% YoY to $172.3 million. Adjusted EBITDA for the quarter was $18.2 million, up 14.5% YoY. Adjusted net income grew 12.4% YoY to $10.2 million while adjusted diluted EPS was $0.58 compared to $0.53 in Q2 2013. Adam D. Singer, M.D., CEO of IPC The Hospitalist Company, said, "Our second quarter results demonstrate the continued strength and effectiveness of our business model with double digit growth in net revenues, adjusted EBITDA and adjusted net income. This solid performance reflects a 22% increase in headcount as a result of both organic hires and acquisitions." The Company anticipates full year 2014 revenues to be in the range of $720 million to $732 million and adjusted diluted EPS to be in the range of $2.41 to $2.51. The full research reports on IPC The Hospitalist Company are available to download free of charge at:

http://www.analystsreview.com/Jul-29-2014/IPCM/report.pdf

--
Healthways Inc. Research Reports
On July 23, 2014, Healthways Inc. (Healthways) reported its Q2 2014 financial results with revenues of $180.6 million, up 11.3% YoY. Net loss was $0.5 million, or $0.01 per share compared to a net loss of $1.1 million, or $0.03 per share in Q2 2013. "Our financial results for the second quarter were consistent with our expectations," commented Ben R. Leedle, Jr., President and CEO of Healthways. "We have now generated four consecutive quarters of sequential-quarter revenue growth." The Company anticipates 2014 revenues to be in the range of $730 million to $760 million while net loss per share is expected to be in the range of $0.02 to $0.17. The full research reports on Healthways are available to download free of charge at:

http://www.analystsreview.com/Jul-29-2014/HWAY/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review